Status: Recruiting
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).
Participants needed: 320
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: DynamiCure BiotechnologyUpdated: Jun 26, 2025Locations: 35
Eligibility criteria
Male or female patients ≥ 18 years of age. [+56]